標(biāo)題: Titlebook: Gene and Cellular Immunotherapy for Cancer; Book 2022 [打印本頁(yè)] 作者: 麻煩 時(shí)間: 2025-3-21 17:26
書(shū)目名稱Gene and Cellular Immunotherapy for Cancer影響因子(影響力)
書(shū)目名稱Gene and Cellular Immunotherapy for Cancer影響因子(影響力)學(xué)科排名
書(shū)目名稱Gene and Cellular Immunotherapy for Cancer網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Gene and Cellular Immunotherapy for Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Gene and Cellular Immunotherapy for Cancer被引頻次
書(shū)目名稱Gene and Cellular Immunotherapy for Cancer被引頻次學(xué)科排名
書(shū)目名稱Gene and Cellular Immunotherapy for Cancer年度引用
書(shū)目名稱Gene and Cellular Immunotherapy for Cancer年度引用學(xué)科排名
書(shū)目名稱Gene and Cellular Immunotherapy for Cancer讀者反饋
書(shū)目名稱Gene and Cellular Immunotherapy for Cancer讀者反饋學(xué)科排名
作者: 鉗子 時(shí)間: 2025-3-21 21:34 作者: dearth 時(shí)間: 2025-3-22 00:49
Biology of CAR-T Cellsin patients with hematologic malignancies, leading to the FDA approval of five CAR-T cells for relapsed or refractory B cell malignancies. The components of these CARs (the extracellular antigen-binding domain, hinge and transmembrane region, co-stimulatory domains, and activation domain) were metho作者: 首創(chuàng)精神 時(shí)間: 2025-3-22 05:36
Cell Types Used for CAR Generationcer patient. Although this personalized autologous T-cell manufacturing method has many advantages and has resulted in outstanding clinical data in hematologic malignancies, a number of aspects require improvement for cell therapy to impact broader patient populations. The first aspect relates to th作者: Admonish 時(shí)間: 2025-3-22 09:07
Combination Therapeutics with CAR-T Cell Therapyultiple hematological malignancies with potential for long term cure. However, multiple hurdles remain to be overcome. Some issues are inherent to CAR-T cells, such as suboptimal expansion, rapid exhaustion, or rejection. Other problems are related to the immunosuppressive tumor microenvironment, wh作者: Servile 時(shí)間: 2025-3-22 15:58
Safety Switches Used for Cellular Therapiestimes fatal complications. Safety switches are increasingly used to manage serious side effects associated with these advanced cellular therapies. In this chapter, we review safety switches categorized in three classes: (a) metabolic (gene-directed enzyme prodrug therapy, GDEPT), (b) dimerization-in作者: Servile 時(shí)間: 2025-3-22 19:27 作者: Autobiography 時(shí)間: 2025-3-22 23:01 作者: 沉思的魚(yú) 時(shí)間: 2025-3-23 03:13 作者: 披肩 時(shí)間: 2025-3-23 06:38
Bringing CAR-T to the ClinicA) approval was in 2017 for CD19-directed CAR-T cell therapy using tisagenlecleucel (tisa-cel) for the treatment of pediatric patients (up to age 25) with relapsed or refractory (R/R) B-acute lymphoblastic leukemia (B-ALL). That same year, CD19 CAR-T cell therapy with axicabtagene ciloleucel (axi-ce作者: 漫步 時(shí)間: 2025-3-23 12:05
CAR-T Cell Complicationsrelapsed and/or refractory B-cell malignancies. Multiple CD19-directed and now a B cell maturation antigen (BCMA) CAR T-cell therapies have been approved for use. Despite their differences, they all share the same toxicities and risks to patients. Cytokine release syndrome (CRS) and immune effector 作者: 顛簸下上 時(shí)間: 2025-3-23 16:18
Mechanisms of Resistance and Relapse After CAR-T Cell Therapynd real-world data, however, reveal that most patients will not achieve durable remission. Therapeutic failure appears to segregate into two distinct models: inherent resistance, in which there is no meaningful disease response after treatment, or acquired resistance, in which disease recurrence fol作者: Rotator-Cuff 時(shí)間: 2025-3-23 21:38 作者: 膽小懦夫 時(shí)間: 2025-3-24 00:11 作者: 蟄伏 時(shí)間: 2025-3-24 04:46 作者: FLASK 時(shí)間: 2025-3-24 09:23
Mechanisms of Resistance and Relapse After CAR-T Cell Therapyusion or that develops after delivery to patients. In this chapter, we review the mechanistic and correlative studies investigating resistance to CAR-T cells, and discuss strategies designed to overcome this significant hurdle to the broader success of this therapy.作者: Commonwealth 時(shí)間: 2025-3-24 14:13
The History of Cellular Therapiesable achievements in medicine are built upon thousands of years of advancement in the understanding of cancer and immunity with rapid acceleration in the last few decades. In this chapter, we will broadly review historical aspects of gene and cellular therapy?development, focusing on major milestones.作者: Gorilla 時(shí)間: 2025-3-24 17:01 作者: Cardiac-Output 時(shí)間: 2025-3-24 19:02
Off-the-Shelf CAR-Ttherapies stem from utilizing autologous patient T cells as the starting material to generate CAR-T. Here we will describe the limitations of autologous CAR-T, the advantages and hurdles of allogeneic donor CAR-T, the learnings from clinical trials using allogeneic CART19 and discuss the future direction of the field.作者: 窩轉(zhuǎn)脊椎動(dòng)物 時(shí)間: 2025-3-25 00:01
Margaret M. Stark,Guy A. Norfolkrs will be presented. These foundational concepts will be useful for understanding later chapters which largely deal with the purposeful engineering of immune cells for adoptive cellular therapies. An attempt has been made to highlight recent review articles for further reading, with an emphasis on those that involve tumor immunology.作者: 遠(yuǎn)足 時(shí)間: 2025-3-25 03:22 作者: 飛來(lái)飛去真休 時(shí)間: 2025-3-25 11:16 作者: 煩人 時(shí)間: 2025-3-25 15:42 作者: cushion 時(shí)間: 2025-3-25 15:49 作者: 純樸 時(shí)間: 2025-3-25 23:35
René Carbonneau,Richard E. Tremblayon of the CAR components, preventing anti-CAR immunity, and/or armoring the cell to respond to its surroundings. While the FDA approved CAR-T cells target two B cell antigens, CD19 and B cell maturation antigen (BCMA), additional targets for B cell malignancies, other hematologic cancers, and solid 作者: 良心 時(shí)間: 2025-3-26 01:22 作者: 膝蓋 時(shí)間: 2025-3-26 05:25 作者: SOB 時(shí)間: 2025-3-26 12:26 作者: 魅力 時(shí)間: 2025-3-26 13:15
Nils A. Loewen MD, PhD,Angelo P. Tanna MDn’s severity and the unmet medical need. This chapter focuses on US Food and Drug Administration (FDA) regulatory considerations for human cellular immunotherapy products used for the treatment of cancer, including genetically-modified cellular immunotherapies.作者: 下垂 時(shí)間: 2025-3-26 20:34 作者: Muscularis 時(shí)間: 2025-3-27 00:20
Crimean – Congo Hemorrhagic Fevernimized via appropriate and timely interventions described herein such that the majority can be treated safely. Additional issues including prolonged cytopenias, on-target but off-tissue B-cell cytotoxicity and resulting aplasia and hypogammaglobulinemia, the theoretical development of replication-c作者: 無(wú)力更進(jìn) 時(shí)間: 2025-3-27 02:49
Clinical Guide to Exposure Therapy using mouse models beginning in the first half of the twentieth century led to pioneering work carried out by the group led by Steven A. Rosenberg at the Surgery Branch of the National Cancer Institute (NCI) that developed adoptive cellular therapy (ACT) with tumor infiltrating lymphocytes (TIL). N作者: curettage 時(shí)間: 2025-3-27 09:02 作者: CESS 時(shí)間: 2025-3-27 11:01 作者: arthrodesis 時(shí)間: 2025-3-27 15:05 作者: 濃縮 時(shí)間: 2025-3-27 18:00
Combination Therapeutics with CAR-T Cell Therapyer strategies involve combining existing CAR-T therapies with other treatment modalities. In this chapter, we will focus on combination strategies that are currently being used and/or are under exploration. We will first discuss strategies used to increase CAR-T effectiveness through combination wit作者: 饒舌的人 時(shí)間: 2025-3-27 22:18
Manufacturing of CAR-T Cells: The Assembly Linecell manufacturing platforms are highlighted in the context of recent clinical trials. Quality requirement and quality control assays enabling the release of clinical CAR-T cell products for infusion are also underscored. The broadening of the scope of CAR-T cell applications beyond cancer therapies作者: Pantry 時(shí)間: 2025-3-28 04:06
Navigating Regulations in Gene and Cell Immunotherapyn’s severity and the unmet medical need. This chapter focuses on US Food and Drug Administration (FDA) regulatory considerations for human cellular immunotherapy products used for the treatment of cancer, including genetically-modified cellular immunotherapies.作者: 粗糙濫制 時(shí)間: 2025-3-28 09:32 作者: misanthrope 時(shí)間: 2025-3-28 12:37
CAR-T Cell Complicationsnimized via appropriate and timely interventions described herein such that the majority can be treated safely. Additional issues including prolonged cytopenias, on-target but off-tissue B-cell cytotoxicity and resulting aplasia and hypogammaglobulinemia, the theoretical development of replication-c作者: 老人病學(xué) 時(shí)間: 2025-3-28 18:07
Tumor Infiltrating Lymphocytes (TIL): From Bench to Bedside using mouse models beginning in the first half of the twentieth century led to pioneering work carried out by the group led by Steven A. Rosenberg at the Surgery Branch of the National Cancer Institute (NCI) that developed adoptive cellular therapy (ACT) with tumor infiltrating lymphocytes (TIL). N作者: 摘要 時(shí)間: 2025-3-28 21:15 作者: Ambiguous 時(shí)間: 2025-3-29 01:05 作者: 古代 時(shí)間: 2025-3-29 03:48 作者: MOAT 時(shí)間: 2025-3-29 09:41
René Carbonneau,Richard E. Tremblayin patients with hematologic malignancies, leading to the FDA approval of five CAR-T cells for relapsed or refractory B cell malignancies. The components of these CARs (the extracellular antigen-binding domain, hinge and transmembrane region, co-stimulatory domains, and activation domain) were metho作者: nauseate 時(shí)間: 2025-3-29 11:56 作者: Vulvodynia 時(shí)間: 2025-3-29 17:14 作者: 一條卷發(fā) 時(shí)間: 2025-3-29 21:17 作者: 過(guò)時(shí) 時(shí)間: 2025-3-30 02:50 作者: Mhc-Molecule 時(shí)間: 2025-3-30 06:28 作者: Synthesize 時(shí)間: 2025-3-30 09:59 作者: Injunction 時(shí)間: 2025-3-30 14:25
Anabolic Effects of MOPs: Cortical Drifting,A) approval was in 2017 for CD19-directed CAR-T cell therapy using tisagenlecleucel (tisa-cel) for the treatment of pediatric patients (up to age 25) with relapsed or refractory (R/R) B-acute lymphoblastic leukemia (B-ALL). That same year, CD19 CAR-T cell therapy with axicabtagene ciloleucel (axi-ce作者: 自制 時(shí)間: 2025-3-30 18:30
